Data protection and life sciences

Personal data is at the very core of every life science business. Life sciences companies handle significant amounts of personal data and are reliant upon the collection and use of personal data, which often includes sensitive health-related data, in order to carry out key business functions. For example, conducting clinical trials on patients, collecting data on drug safety and adverse reactions in order to comply with pharmacovigilance requirements, and collecting genetic information for the development of personalised medicines all rely on the collection and processing of data relating to individual data subjects. Consequently, it is vitally important that life sciences companies understand, and are in compliance with, the strict rules that apply to the processing of personal data.

This Overview provides an introduction to the application of the data protection regimes to key areas of the life sciences under the EU General Data Protection Regulation, Regulation (EU) 2016/679 (EU GDPR) and the United Kingdom General Data Protection Regulation, Assimilated Regulation (EU) 2016/679 (UK GDPR) (together the ‘GDPR regimes’).

Assimilated law is the name given to retained EU law (‘REUL’) which remains in force after

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

TAKE A FREE TRIAL

Latest Life Sciences News

Parliament's public health committee adopts new rules to strengthen supply of critical medicines

The European Parliament's public health committee has adopted new measures aimed at strengthening the availability and security of supply of critical medicines in the EU, tackling persistent shortages of essential drugs such as antibiotics, insulin, vaccines and treatments for chronic diseases. The draft rules propose to boost investment in EU manufacturing capacity, establish strategic projects and a dedicated security fund, encourage collaborative cross-border procurement, and improve supply chain resilience to reduce dependence on third-country suppliers. The legislation also seeks to enhance public health protection and competitiveness in the pharmaceutical sector. Parliament is expected to adopt its position during the January 2026 plenary session, with negotiations with EU governments set to follow.

Team-NB outlines approach for managing down-classification of SARS-CoV-2 IVD tests

Team-NB has published a position paper detailing how IVD Notified Bodies will manage the down-classification of SARS-CoV-2 tests following the MDCG 2020-16 rev.4 update, which reclassifies SARS-CoV-2 tests. Professional-use tests will move from Class D to Class B, self-testing devices to Class C, and multiplex devices will be assessed case by case. Manufacturers must submit a change notification with updated technical documentation, risk management files, and classification justification. Notified Bodies will review these changes and adjust certification processes accordingly.

EMA publishes three-year work plans for five working groups

The European Medicines Agency (EMA) has published three-year work plans for five working groups: Biosimilars, Biologics, joint CHMP/CVMP Quality, Non-clinical domain and Synthetic Peptides, covering the period 2026–2028. The plans outline strategic and tactical goals including advancing regulatory science, harmonising EU and international guidelines, and supporting innovation in medicines development. Key priorities include guidance on biosimilar comparability and tailored clinical approaches, quality aspects for biologicals and RNA vaccines, risk-based strategies for chemical and biological active substances, integration of new approach methodologies (NAMs) and replacement, reduction and refinement (3Rs) principles in non-clinical testing, and publication of a guideline on synthetic peptides addressing manufacturing, characterisation and control requirements.

Council and Parliament agree on new rules to enhance efficiency in pharmaceutical sector

The Council of the EU and the European Parliament have reached a provisional agreement on reforming the EU’s pharmaceutical framework, focusing on patient access, regulatory efficiency, industry competitiveness, and medicinal supply security, with incentives to address antimicrobial resistance. Under the agreement, new medicines will receive eight years of data exclusivity and one year of market protection post-authorisation and Article 56a will allow Member States to require sufficient medicine supplies to meet national demands. The EU pharma package will also expand activities for generic/biosimilar manufacturers for market entry post-IP rights expiry, including procurement tenders and introduce a transferrable exclusivity voucher, granting one extra year of protection for developing priority antimicrobials, among other things. The provisional agreement will need to be endorsed by the Council and Parliament, before it is formally adopted and published in the Official Journal of the EU.